Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
NCT01310686 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2018-10-12
Summary
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
Conditions
Sponsors & Collaborators
-
Genentech, Inc.
collaborator INDUSTRY -
West Coast Retina Medical Group, Inc.
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-04-30
- Primary Completion
- 2019-06-30
- Completion
- 2019-06-30
Countries
- United States
Study Locations
More Related Trials
-
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)
NCT02762188 ·Status: COMPLETED ·Phase: NA
-
Genetic Study of Age-Related Macular Degeneration
NCT00357578 ·Status: COMPLETED
-
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
NCT00320788 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
NCT00320775 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
NCT01024998 ·Status: COMPLETED ·Phase: PHASE1
-
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
NCT05984927 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
AAVCAGsCD59 for the Treatment of Wet AMD
NCT03585556 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
NCT01624636 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
NCT00090532 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
NCT06817343 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
NCT01482910 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
NCT01255462 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT02399072 ·Status: TERMINATED
-
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
NCT00527423 ·Status: COMPLETED ·Phase: PHASE2
-
Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration
NCT03630562 ·Status: COMPLETED ·Phase: NA
-
Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
NCT00509548 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
NCT03144999 ·Status: COMPLETED ·Phase: PHASE1
-
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
NCT03468296 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
NCT02859766 ·Status: COMPLETED ·Phase: PHASE1
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
NCT00509795 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
NCT06888492 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
NCT05099094 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Recurrent Neovascular Age-related Macular Degeneration After Therapy Suspension
NCT04659512 ·Status: COMPLETED
-
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
NCT01535950 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
NCT03066258 ·Status: COMPLETED ·Phase: PHASE1/PHASE2